Reslizumab

Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5).[1] Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-relate... [wikipedia]